This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised

Idenix Pharmaceuticals (IDIX) will use the $107 million raised Tuesday to push ahead with the clinical development of hepatitis C drugs, despite the Street's perception that the company's efforts are too little, too late. The new cash also ensures Idenix's legal team has the resources necessary to continue patent litigation against Gilead Sciences (GILD - Get Report), says Idenix CEO Ron Renaud.

I reached Renaud by phone Tuesday morning. He sounded happy, which isn't surprising for a guy who's about to deposit a check into Idenix's bank account that will almost double the company's cash reserves.

The Baupost Group raised its ownership stake in Idenix from 27% to 35% by purchasing 16.4 million shares of common stock at $6.50 per share -- a 5% discount to Idenix's Monday close.

The registered direct offering raises $107 million for Idenix, which had $122 million in cash on hand at the end of 2013.

Must Read: Ariad Pharma Short Seller Explains Why Takeover Rumor Is Bunk

"I know there's a perception that we're late to [hepatitis C] but the market will take a long time to play out and there will be plenty of room to operate when we get there," said Renaud.

For Idenix, that means continuing the development of its lead nucleotide prodrug IDX21437 and the NS5A inhibitor samatasvir (also known as IDX719.) Renaud and his team are betting that these two drugs (or follow-on compounds in Idenix's labs) could be combined into a single, daily pill to treat all hepatitis C genotypes with a high barrier to resistance. The idea is not for Idenix to compete with Gilead, Abbvie (ABBV - Get Report) or Bristol-Myers Squibb (BMY - Get Report) today (way too late for that) but to leapfrog ahead and be ready to compete for hepatitis C patients in 2017-2018.

"We're running big programs so we need "big n" studies in order to catch up," said Renaud. By "big n", Renaud means Idenix needs to run large clinical studies with lots of hepatitis C patients enrolled.

What if Idenix can't catch up in hepatitis C? Is the company considering a Plan B?

"We need to stick to what we know," said Renaud, which means virology. "We're still committed to demonstrating strategic success in hepatitis C even though I know our track record there to date hasn't been great."

Renaud is starting to talk a little bit using the company's expertise in nucleotide and prodrug chemistry to possibly develop drugs in infectious disease and oncology. Renaud notes, for example, that patients with acute myeloid leukemia are already treated with a nucleoside that is toxic and relatively ineffective, which opens an opportunity for a prodrug which could improve exposure and/or the safety profile.

"We have an open mind about bolstering the pipeline. I know we're small and competing for good ideas but we're not opposed to anything that creates value to shareholders," said Renaud.

He adds: "I realize that sounds like a CEO cliche but it's the truth."

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs